Opioid Free Techniques

This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.

Go to the Main Page to see the Topic Outline.

Go to the Generalized Suggested Outline for information on case-specific details for each page.

Go to the Test Page for examples on how to use references in the page.

Relevant Article Depot:

Bringing Back the Balance: Opioid Reduction in Anesthesia

Outcomes for 41 260 pediatric surgical patients with opioid-free anesthesia: One center's experience.

Evidence for the Efficacy of Systemic Opioid-Sparing Analgesics in Pediatric Surgical Populations: A Systematic Review.

Rational Perioperative Opioid Management in the Era of the Opioid Crisis.

Opioids and Public Health: The Prescription Opioid Ecosystem and Need for Improved Management.

Opioid-free anaesthesia reduces postoperative nausea and vomiting after thoracoscopic lung resection: a randomised controlled trial Association of Intraoperative Opioid Administration With Postoperative Pain and Opioid Use. JAMA surgery 2023;158:854-64.

Intraoperative opioid and non-opioid administration patterns and early postoperative pain: A single-center retrospective longitudinal study. Journal of opioid management 2019;15:389-405.

Opioid-free versus opioid-based anesthesia in pancreatic surgery. BMC Anesthesiol 2022;22:9. Correction

Opioid-free Anesthesia and Analgesia in Clinical Practice: Considerations, Techniques, and Limitations

Suzetrigine

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials

Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain

Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1. 8 pain signal inhibitor for the treatment of moderate to severe pain

Selective inhibition of NaV1. 8 with VX-548 for acute pain

Suzetrigine for acute postoperative pain: a systematic review and meta-analysis of current evidence

Targeting Nav1.8 with the nonopioid antagonist suzetrigine for analgesia: cause for optimism?